Diagnostic procedure of the obstructive sleep apnea-hipopnea syndrome (sahs) through the quantification of the expression of phd2 and/or phd3. (Machine-translation by Google Translate, not legally binding)

Diagnostic procedure for obstructive sleep apnea-hypopnea syndrome (sahs) by quantifying the expression of phd2 and/or phd3. The present invention relates to a method for the diagnosis and monitoring of response to the treatment of obstructive sleep apnea-hypopnea syndrome (sahs) in humans by quantitatively determining the expression of the prolyl hydroxylase 3 gene (phd3 = egln3 = hph2), characterized in that the determination is performed on peripheral blood leukocytes. An alternative gene for the same purpose is the prolyl hydroxylase 2 gene (phd2 = egln1 = hphp1). In particular, the phd3 and phd2 genes encode two prolylhydroxylases involved in the degradation of inducible transcription factors by hypoxia hif (hypoxia-inducible factor). (Machine-translation by Google Translate, not legally binding) Procedimiento de diagnóstico del síndrome de apnea-hipopnea obstructiva del sueño (SAHS) mediante la cuantificación de la expresión de PHD2 y/o PHD3. La presente invención se refiere a un procedimiento para el diagnóstico y la monitorización de respuesta al tratamiento del síndrome de apnea-hipopnea obstructiva del sueño (SAHS) en humanos mediante la determinación cuantitativa de la expresión del gen prolilhidroxilasa 3 (PHD3 = EGLN3 = HPH2), caracterizado porque la determinación se realiza en leucocitos de sangre periférica. Un gen alternativo para el mismo fin es el gen de la prolilhidroxilasa 2 (PHD2 = EGLN1 = HPHP1). En concreto, los genes PHD3 y PHD2 codifican dos prolilhidroxilasas implicadas en la degradación de los factores de transcripción inducible por hipoxia HIF (del inglés, Hypoxia-Inducible Factor).